Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
36.60
+0.66 (1.82%)
At close: Oct 16, 2025, 4:00 PM EDT
35.87
-0.73 (-1.98%)
After-hours: Oct 16, 2025, 6:09 PM EDT
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $1.30M in the quarter ending June 30, 2025, with 1,200.00% growth. This brings the company's revenue in the last twelve months to $1.40M, down -24.45% year-over-year. In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$1.40M
Revenue Growth
-24.45%
P/S Ratio
378.64
Revenue / Employee
$8,696
Employees
161
Market Cap
530.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
Dec 31, 2022 | 1.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 2 months ago - Inhibrx Reports Second Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Inhibrx Reports First Quarter 2025 Financial Results - PRNewsWire
- 7 months ago - Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PRNewsWire
- 7 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - PRNewsWire
- 9 months ago - Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PRNewsWire
- 9 months ago - Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PRNewsWire
- 1 year ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 1 year ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha